Beveridge, now with Avalere Health, addressed the importance of clinical pathways in selecting therapies in non-small cell lung cancer (NSCLC) and the emergence of options for EGFR Exon 20 Insertion+ ...
Conclusions: Lack of phosphorylation of AKT and lack of PTEN expression in the AKT pathway downstream of EGFR may be a mechanism of MPM's clinical resistance to OSI-774. ERK is variably activated ...
The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become ...
Two microscopy images of human colon organoids. The left image shows an organoid with the FBXW7 mutation (colorectal cancer) and the right image shows an organoid without the mutation (wild type). The ...
Drugs that block enzymes called tyrosine kinases are among the most effective targeted therapies for cancer. However, they ...
Edward Arrowsmith, MD, MPH, medical director for clinical pathways for OneOncology, discussed treatment challenges in EGFR Exon 20 insertion+ non-small cell lung cancer (NSCLC) and best practices in ...
Researchers have discovered a cellular partnership that drives the growth of deadly brain tumors and could potentially serve as a novel target for disease treatment. A new study has uncovered a ...
Implementation of a race-neutral eGFR equation contributed to more than 20,000 wait-time modifications and more kidney ...
The Organoid group at the Hubrecht Institute have identified a new link between FBXW7 mutations and EGFR signaling activity. The FBXW7 gene is commonly mutated in colorectal cancer and such mutations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results